Nanotechnology Now - Press Release: "Nanobiotix CEO Dr. Laurent Lévy is elected co-president of the French Technology Platform on Nanomedicine (FTPN)"

Home > Press > Nanobiotix CEO Dr. Laurent Lévy is elected co-president of the French Technology Platform on Nanomedicine (FTPN)

Abstract:
Podcast available at www.medtechmatters.com

Nanobiotix CEO Dr. Laurent Lévy is elected co-president of the French Technology Platform on Nanomedicine (FTPN)

PARIS, France | Posted on June 4th, 2008

Nanobiotix, an emerging nanomedicine company focused on cancer therapy, announced today that its chief executive officer, Laurent Lévy, Ph.D., has been elected as co-president of the French Technology Platform on Nanomedicine (FTPN), effective immediately.

FTPN organizes communication, collaborative work and meetings among the French-based nanomedicine community's stakeholders—such as companies, research institutes, universities, hospitals, and patient associations—with representatives from ministries, regional clusters, government agencies and research foundations.

"I am honored to serve as the co-president of FTPN," said Dr. Lévy. "FTPN's mission is to help accelerate the development of nanomedicine into clinical practice for the benefit of patients. Moving forward, this evolving field of nanomedicine will be a great challenge, one that our committed board members are ready to undertake."

FTPN is the counterpart to the European Technology Platform on Nanomedicine (ETPN) and works to ensure French-based participation in European collaborative projects. Led by market needs and industrial developments, FTPN has the following goals: (1) identify and represent stakeholders; (2) support industrial R&D priorities and initiatives with a strong link and collaborative work with public-focused research; (3) allow emergence of innovative projects in accordance with national and local initiatives; (4) inform, and initiate dialogue with, patient associations and the general public; and (5) link and promote work between regulatory agencies and nanomedicine stakeholders. FTPN's board of directors includes—co-presidents: Dr. Lévy and Gérard Mathis, CSO, Cis-Bio; Patrice Marche representing INSERM and CNRS and Jean-Pierre Benoit representing clinical research; Patrick Boisseau, Executive Board member of the European Technology Platform on Nanomedicine; and, Pierre-Noël Lirsac, French representative to the European Technology Platform Nanomedicine Mirror Group1.

Nanomedicine2 is the application of nanotechnology to achieve breakthroughs in healthcare. It exploits the improved and often novel physical, chemical and biological properties of materials at the nanometer scale. Nanomedicine has the potential to enable early detection and prevention and to essentially improve diagnosis, treatment and follow-up of diseases.

1 Official representative from states member and associated states member from EU.

2 Source: ETPN, Strategic Research Agenda, November 2006.

####

About Nanobiotix
Nanobiotix is an emerging nanomedicine company combining dramatic advances in nanotechnology and molecular biology to develop nanoXray™— a technology platform that is expected to be turned ‘on’ and ‘off’ outside the body to selectively treat a variety of cancers safely and noninvasively. Use of nanoXray is intended to resolve radiation therapy’s biggest drawback: destruction of healthy tissue and its subsequent deleterious side effects when a high dose of Xray is necessary. The core of a nanoXray nanoparticle is an inactive and inert substance—not a drug—that can be activated to locally (intratumor) increase the dose of Xray, which is then expected to lead to higher efficiency. After nanoXray nanoparticles accumulate in the target tissues, a standard X-ray is applied that is intended to generate a local therapeutic effect, designed to destroy only the targeted tumor cells. This mechanism suggests total control of the intended therapeutic effect.

For more information, please click here

Contacts:
Ronald Trahan Associates Inc.
Ronald Trahan, APR
508-359-4005, x108

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: